Halozyme Therapeutics, Inc. reported $1.66B of revenue over the trailing twelve months, +41% on the year before. 11 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $1.66B (to Q2 2026). Net income: $414M, trailing twelve months to Q2 2026. Free cash flow: $806M, trailing twelve months to Q2 2026. Operating margin: 37%, trailing twelve months to Q2 2026.

HALOHalozyme Therapeutics, Inc.

Healthcare

$110.41+42% 1Y

$110.41

$61.6352 weeks$115.27

HALO as reported

Halozyme Therapeutics, Inc. reported $1.66B of revenue over the trailing twelve months, +41% on the year before. 11 reported series are charted on this page, each one as filed.

$1.66B

Revenue, trailing twelve months · to Q2 2026 · +41% against the twelve months before

Net income: $414M
Net income · −26% year on year · trailing twelve months to Q2 2026
Free cash flow: $806M
Free cash flow · +49% year on year · trailing twelve months to Q2 2026
Operating margin: 37%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for HALO, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$1.66B	+41%	Q2 2026
Net income	$414M	−26%	Q2 2026
EPS	$3.43	−22%	Q2 2026
Gross margin	82%	n/a	Q2 2026
Operating margin	37%	n/a	Q2 2026
Net margin	26%	n/a	Q2 2026
ROE	304%	n/a	Q2 2026
ROA	17%	n/a	Q2 2026
ROIC	24%	n/a	Q2 2026
Free cash flow	$806M	+49%	Q2 2026
P/E	32.2	n/a	today

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.